From: Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
HER2
EGFR
ALK/ROS1
KRAS
P value
n
25
74
39
40
ORR%
36.0
33.8
41.3
35.0
0.896
DCR%
92.0
78.4
87.2
72.5
0.139